p16 gene alterations in locally advanced squamous cell carcinoma of the head and neck

Oncology Reports

Volumn 15, Issue 3, 2006, Pages 661-665

  Wang, Dian ^a,b   Grecula, John C ^a   Gahbauer, Reinhard A ^a   Schuller, David E ^a   Jatana, Kris R ^a   Biancamano, John D ^a   Lang, James C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Chemotherapy; p16 gene; Radiotherapy; Squamous cell carcinoma of the head and neck

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; TREATMENT OUTCOME;

EID: 33645728168     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.3.661     Document Type: Article

References (21)

1. Zhang S-Y, Klein-Szanto A, Sauter ER, et al: Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 55: 505-509, 1955.
2. Reed AL, Califano J, Cairns P, et al: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56: 3630-3633, 1996. (Pubitemid 26272001)
3. Olshan AF, Weissler MC, Pei H, et al: Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogene 14: 811-818, 1997. (Pubitemid 27100025)
4. Lang JC, Tobin EJ, Knobloch TJ, et al: Frequent mutation of p16 in squamous cell carcinoma of the head and neck. Laryngoscope 108: 923-928, 1998. (Pubitemid 28299913)
5. Fizzotti M, Cimino G, Pisegna S, et al: Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 10: 2685-2690, 1995.
6. Reed JA, Loganzo F, Shea CR, et al: Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 55: 2713-2718, 1995.
7. Adelstein DJ, Tan EH and Lavertu P: Treatment of head and neck cancer: the role of chemotherapy. Crit Rev Oncol Hematol 24: 97-116, 1996. (Pubitemid 26292544)
8. Vokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck cancer. N Engl J Med 328: 184-194, 1993.
9. Fu KK: Combined-modality therapy for head and neck cancer. Oncology 11: 1781-1796, 1997.
10. Laramore GE, Scott CB, Al-Sarraf M, et al: Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on intergroup study 0034. Int J Radiat Oncol Biol Phys 23: 705-713, 1992.
11. Head and Neck Contracts Program: Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the head and neck contacts program. Cancer 60: 301-311, 1987.
12. Adelstein DJ, Saxton JP, Lavertu P, et al: A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck 19: 567-575, 1997. (Pubitemid 27407310)
13. Brizel DM, Albers ME, Fisher SR, et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338: 1798-1804, 1998. (Pubitemid 28277960)
14. Calais G, Alfonsi M, Bardet E, et al: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst 91: 2081-2086, 1999. (Pubitemid 30019568)
15. Grecula JC, Schuller DE, Rhodes CA, et al: Intensification regimen 2 for advanced head and neck squamous cell carcinomas. Arch Otolaryngol Head Neck Surg 125: 1313-1318, 1999.
16. Okamoto A, Demetrick DJ, Spillare EA, et al: P16INK4 mutations and altered expression in human tumors and cell lines. Cold Spring Harb Symp Quant Biol 59: 49-57, 1994.
17. Merlo A, Herman JG, Mao L, et al: 5′ CgG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692, 1995.
18. Lilischkis R, Sarcevic B, Kennedy C, et al: Cancer-associated mis-sense and deletion mutations impair p16Ink4 CDK inhibitary activity. Int J Cancer 66: 249-254, 1996. (Pubitemid 26248209)
19. ARF. Int J Oncol 21: 401-408, 2002.
20. Parry D, Bates S, Mann DJ, et al: Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumor suppressor gene product. Eur Mol Biol Org J 14: 503-511, 1995.
21. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using Real time quantitative PCR and the 2-ΔΔCT method. Methods 25: 402-408, 2001. (Pubitemid 34164012)